Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 18683999)


Smoking behaviour and mental health disorders--mutual influences and implications for therapy.

Minichino A, Bersani FS, Calò WK, Spagnoli F, Francesconi M, Vicinanza R, Delle Chiaie R, Biondi M.

Int J Environ Res Public Health. 2013 Oct 10;10(10):4790-811. doi: 10.3390/ijerph10104790. Review.


Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.

Pachas GN, Cather C, Pratt SA, Hoeppner B, Nino J, Carlini SV, Achtyes ED, Lando H, Mueser KT, Rigotti NA, Goff DC, Evins AE.

J Dual Diagn. 2012;8(2):117-125. Epub 2012 May 11.


A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia.

Yousefi MK, Folsom TD, Fatemi SH.

J Addict Res Ther. 2011 Dec 20;S4(1). pii: 3045.


Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL.

Neuropsychopharmacology. 2012 Feb;37(3):660-8. doi: 10.1038/npp.2011.238. Epub 2011 Nov 2.


The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.

Wildeboer-Andrud KM, Stevens KE.

Pharmacol Biochem Behav. 2011 Nov;100(1):17-24. doi: 10.1016/j.pbb.2011.07.001. Epub 2011 Jul 7.


Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.

Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE.

Psychopharmacology (Berl). 2012 Jan;219(1):25-34. doi: 10.1007/s00213-011-2373-6. Epub 2011 Jun 22.


Varenicline for tobacco dependence: panacea or plight?

Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, Foulds J.

Expert Opin Pharmacother. 2011 Aug;12(11):1799-812. doi: 10.1517/14656566.2011.587121. Epub 2011 Jun 6. Review.


Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.

Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL.

Schizophr Res. 2011 Jun;129(1):94-5. doi: 10.1016/j.schres.2011.02.003. Epub 2011 Mar 4. No abstract available.


Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments.

Sarter M, Lustig C, Taylor SF.

Neuropharmacology. 2012 Mar;62(3):1544-53. doi: 10.1016/j.neuropharm.2010.12.001. Epub 2010 Dec 13. Review.


A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities.

Moss TG, Weinberger AH, Vessicchio JC, Mancuso V, Cushing SJ, Pett M, Kitchen K, Selby P, George TP.

Am J Addict. 2010 Jul-Aug;19(4):293-311. doi: 10.1111/j.1521-0391.2010.00051.x. Review.


Visual hallucinations associated with varenicline: a case report.

Raidoo BM, Kutscher EC.

J Med Case Rep. 2009 May 8;3:7560. doi: 10.1186/1752-1947-3-7560.


Treatment of tobacco dependence in mental health and addictive disorders.

Hitsman B, Moss TG, Montoya ID, George TP.

Can J Psychiatry. 2009 Jun;54(6):368-78. Review.


Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings.

Hall SM, Prochaska JJ.

Annu Rev Clin Psychol. 2009;5:409-31. doi: 10.1146/annurev.clinpsy.032408.153614. Review.


Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline.

McClure JB, Swan GE, Jack L, Catz SL, Zbikowski SM, McAfee TA, Deprey M, Richards J, Javitz H.

J Gen Intern Med. 2009 May;24(5):563-9. doi: 10.1007/s11606-009-0926-8. Epub 2009 Feb 24. Erratum in: J Gen Intern Med. 2009 Oct;24(10):1173.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk